Latest Healthcare News

Epsilon Healthcare delivered record September-quarter customer receipts of A$3.9 million, while nine-month revenue reached A$11.5 million. The growth story is strengthening, but cash fell to A$997,000 and quarterly operating cash flow remained negative.

Cann Group’s September quarter delivered a sharp increase in revenue and exports as its Mildura GMP facility gained traction in Europe. But with just $49,000 in cash, $626,000 of undrawn debt capacity and an estimated 0.9 quarters of funding, the recovery still depends on collections and further financing.

Vitasora Health has signed a Florida healthcare agreement covering an initially addressable 9,000 Medicare patients while estimated October billable care minutes rose 50%. The ASX-listed company also agreed terms for an A$3 million secured facility, but the funding is not yet drawn and carries approval, interest and dilution conditions.

Doctor Care Anywhere’s Q3 revenue rose 16% to £11.3 million as its weight-management business delivered its first full quarter, lifting subscription revenue to 19% of the total. The unaudited update also shows modest consultation growth, higher cash and three new distribution partnerships.

ImpediMed lifted quarterly revenue and recurring revenue, but weaker-than-expected BCRL sales and a near-total sales team rebuild have put its path to cash-flow break-even under pressure. The company ended September with $11.6 million in cash and 4.7 quarters of funding at the quarter’s operating burn.

Cyclopharm has reported record third-quarter US Technegas revenue of A$1.62 million, with 76% generated by recurring consumable orders. Its installed base and hospital pipeline expanded sharply after new clinical guidelines preferred Technegas when available, while quarterly cash burn fell to A$0.9 million.

Emyria has reported record quarterly revenue of approximately $1.42 million after opening its first Sydney Empax clinic and expanding national treatment capacity. The growth comes with $2.28 million in operating cash outflows and an estimated 2.08 quarters of funding at quarter-end.

Atomo Diagnostics has signed an MOU with Innovation Scientific to develop a fourth-generation HIV rapid test using its Galileo cassette. The project could add a new product to Atomo’s pipeline, but regulatory approval, clinical work and definitive commercial agreements remain outstanding.

Integral Diagnostics has opened FY27 below expectations, with radiologist and sonographer shortages limiting revenue growth and pushing labour costs ahead of sales. The company expects FY27 revenue growth of 4% to 6% and a full-year operating EBITDA margin of 19.5% to 20.5%, with improvement weighted to the second half.

Saluda Medical delivered a strong operational start to FY27, with US implants up 55% and quarterly revenue rising 26% to US$23.1 million. But the medical device company ended September with US$73.6 million in cash, US$100 million of secured debt drawn and estimated funding for just 2.3 quarters at the quarter’s cash-use rate.

Resonance Health has reported encouraging preliminary results from an investigational MRI software device that identifies liver fibrosis without additional scanner hardware. The early data are promising, but the model remains unverified and regulatory clearance is still ahead.

Adheris Health delivered a stronger first quarter on revenue, margins and its CY27 sales pipeline, but ended September with US$3.5 million in cash after a US$3.1 million operating outflow. The company also disclosed the impending loss of a major pharmacy partner and a US$2.3 million-plus legal claim.